Teva
Manufacturing · Israel · 10K+ Employees
View Company Info for Free
Overview
Headquarters
124 Dvora Hanevi'a St, Tel Aviv, Tel Avi...Phone Number
+972 39148213Website
www.tevapharm.comRevenue
$17.3 BillionStock Symbol
TEVAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
2
1
About Teva
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is dedicated to addressing unmet patient needs by advancing scientific research, expanding access to quality medicines, and streamlining the delivery of treatments -from established generics to cutting-edge therapeutic solutions.Explore more
Teva Org Chart
YK
Director, Financial & Chief Financial Officer...
AJ
Chief Financial Officer (Asia Pacific, Japan)
NB
Regional Director, Finance & Chief Financial ...
CO
Global Chief Financial Officer, Operations
EY
Senior Vice President, Chief Financial Office...
EK
Chief Financial Officer & Executive VP
MB
Chief Financial Officer
PA
Board Director and Group Chief Financial Offi...
DP
Chief Financial Officer (Israel)
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Teva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Teva is spiking on competitors!
Funding: Get notified immidiatlly once Teva has new funding data
Teva, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Teva has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Teva
Product Launch: Get notified when Teva launches new products
Earning: See what the market has to say on Teva recently announced quarterly report
Click to see if Teva had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Teva as Masked Content
Find more new buyers
Explore company insights
Get a deeper look into Teva's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Teva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teva.
Teva financials insights
Gather financial insights about Teva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Multiple Rounds
$11.3B
2012
Multiple Rounds
$7.6B
2015
Debt
$2.4B
Debt
$33.8B
2016
Multiple Rounds
$28.1B
2018
Corporate Investment
$358M
Debt
$4.5B
2019
Debt
$2.3B
2026
Private Equity
$400M
Teva Tech Stack
A closer look at the technologies used by Teva
See more technologies
Most Recent Scoops
Earnings
reported net debt of $12.9 billion at the end of Q2 2026, with a net debt to EBITDA ratio of 2.8x (2.3x excluding the MLX acquisition), and remains on track to achieve its target of below 2x net debt to EBITDA by 2027.
Business Finance, Finance, Financing & Debt
Project
Teva has outlined a pipeline launch sequence targeting one new asset per year over the next five years, including Olanzapine LAI in 2026, Ecopipam in 2027, and DARI and additional assets through 2028 to 2030, with combined pipeline peak sales potential of over $10 billion.
Earnings
reported that its biosimilar portfolio has grown to 15 products in market with 14 more in the pipeline, with 2 out of 5 US biosimilar products ranked number one, and the company on track to exceed its $800 million biosimilar revenue target by 2027.
Pharmaceuticals
Project
Teva has announced that its DARI dual-action rescue inhaler study for asthma is fully enrolled with over 2,700 patients, with the final event forecast by end of 2026 and data presentation expected in the first half of 2027.
Pharmaceuticals, Clinical Operations
Earnings
Corporate Strategy, Finance, Financial Operations
Teva News & Media
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities. “Teva appreciates the opportunity to worTeva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, a first in class pediatric Tourette syndrome treatment. Despite the share price easing around 3% over the last day and 2% over the past week, Teva Pharmaceutical Industries has a 1 month share price return of about 4% and a year to date share price return of around 18%, while total shareholder returnTeva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing ...
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions. Transaction reflects Teva’s targeted business development approach focused on strategic fit,Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA review
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teva
Sign Up For FreeTo access detailed company insights
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is... Read More
